2 
A roster of the members of the Institutional Biosafety Conmittee 
( IBC) shall be submitted to ORDA. This must include the names, addresses, 
occupations, qualifications, and curricula vitae of the chairperson and 
members of the committee. The information should be addressed to: 
Office of Recombinant DMA Activities 
National Institutes of Health 
Building 31, Room 4A52 
Bethesda, Maryland 20014 
The membership of IBCs is subject to review by ORDA for compliance 
with requirements stated in the Guidelines. The Institution shall report 
pronptly to ORDA any changes in this information. 
ORDA will assist in the formation of an Area Biosafety Committee 
(ABC) when appropriate. Such a committee, composed of members from the 
Institution and other organizations beyond its own staff, may be neces- 
sary as an alternative to an IBC when additional expertise from outside 
a given Institution is necessary for the IBC to fulfill its functions. 
I-B. Prior Approval Requirements . 
I-B-l. Activities Requiring Prior Approval . An Institution 
receiving any NIH funds for recombinant DMA research must obtain approval 
from NIH, or another funding agency designated by NIH for this purpose, 
prior to the initiation of the following activities: 
I-B^-l-a. Projects for which containment levels are not explicitly 
specified by the NIH Guidelines or NIH [The setting of containment 
[ 65 ] 
